Vitamin D-related polymorphisms and vitamin D levels as risk biomarkers of COVID-19 infection severity
et al., medRxiv, doi:10.1101/2021.03.22.21254032 (Preprint)
, Vitamin D-related polymorphisms and vitamin D levels as risk biomarkers of COVID-19 infection severity, medRxiv, doi:10.1101/2021.03.22.21254032 (Preprint)
Analysis of 491 hospitalized patients in Portugal showing that polymorphisms in the vitamin D binding protein encoded by the GC gene are related to COVID-19 severity (p = 0.005). There was an association between vitamin D polygenic risk score and vitamin D levels (p = 0.042), and between vitamin D levels and mortality (p = 1.5e-4). Authors conclude that a genetic susceptibility for vitamin D deficiency may explain higher severity in COVID-19.
|
risk of death, 41.2% lower, RR 0.59, p = 0.02, high D levels 23 of 179 (12.8%), low D levels 68 of 311 (21.9%), NNT 11, >20ng/mL.
|
| Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates |
Freitas et al., 27 Mar 2021, retrospective, Portugal, preprint, 36 authors.
Abstract: medRxiv preprint doi: https://doi.org/10.1101/2021.03.22.21254032; this version posted March 26, 2021. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in
perpetuity.
It is made available under a CC-BY-ND 4.0 International license .
Vitamin D-related polymorphisms and vitamin D
levels as risk biomarkers of COVID-19 infection
severity
Ana Teresa Freitas 2,3, Conceição Calhau 4,5, Gonçalo Antunes 2, Beatriz Araújo 11, Matilde
Bandeira 6,15, Sofia Barreira 6,15, Filipa Bazenga 11, Sandra Braz 7, Daniel Caldeira 1,10,
Susana Constantino Rosa Santos 1, Ana Faria 4, Daniel Faria 13,3, Marta Fraga 9, Beatriz
Nogueira-Garcia 10, Lúcia Gonçalves 2, Pavlo Kovalchuk 2, Luísa Lacerda 11, Hugo Lopes 2,
Daniel Luís 2, Fábio Medeiros 8, Ana M. P. Melo 13,14, José Melo-Cristino 9, Ana Miranda 9,
Clara Pereira 2, Ana Teresa Pinto 1, João Pinto 11, Helena Proença 9, Angélica Ramos 11,12,
João P. R. Rato 13,14, Filipe Rocha 1 , Júlio César Rocha 4,5, André Moreira-Rosário 4,5,
Helena Vazão 2, Yuliya Volovetska 9, João-Tiago Guimarães 11,12, Fausto Pinto 1,10*
1 Centro Cardiovascular da Universidade de Lisboa (CCUL), CAML, Faculdade de Medicina,
Universidade de Lisboa, Lisboa, Portugal;
2 HeartGenetics, Genetics and Biotechnology SA, Biocant Park, Portugal;
3 INESC-ID, Instituto Superior Técnico, University of Lisbon, Lisboa, Portugal;
4 Nutrition and Metabolism, NOVA Medical School, Universidade Nova de Lisboa, Lisboa, Portugal;
5 CINTESIS - Center for Health Technology and Services Research, Portugal;
6 Rheumatology Department, Hospital de Santa Maria, Centro Hospitalar Universitário Lisboa Norte,
Centro Académico de Medicina de Lisboa, Lisboa, Portugal;
7 Internal Medicine Department, Santa Maria Hospital, Centro Hospitalar Universitário Lisboa Norte,
Faculdade de Medicina da Universidade de Lisboa, Portugal;
8 Department of Infectious disease, Santa Maria Hospital - CHULN, Lisboa, Portugal;
9 Clinical Pathology Department, Hospital Santa Maria, Centro Hospitalar Universitário Lisboa Norte,
EPE, Lisbon, Portugal;
10 Cardiology Department, Hospital Universitário de Santa Maria - CHULN, Lisboa, Portugal;
11 Serviço de Patologia Clínica, Centro Hospitalar Universitário de São João, Portugal;
12 Departamento de Biomedicina, Faculdade de Medicina, EPIUnit, Instituto de Saúde Pública,
Universidade do Porto, Portugal;
13 Portuguese Infrastructure of Biological Data – BioData.pt, Portugal;
14 Instituto Gulbenkian de Ciência, Oeiras, Portugal;
15 Unidade de Investigação em Reumatologia, Instituto de Medicina Molecular, Faculdade de Medicina,
Universidade de Lisboa, Centro Académico de Medicina de Lisboa, Lisboa, Portugal.
* Correspondence:
Fausto José da Conceição Alexandre Pinto, Centro Cardiovascular da Universidade de Lisboa (CCUL),
CAML, Faculdade de Medicina, Universidade de Lisboa, 1649-028 Lisboa, Portugal, phone: +351 210
008 500, faustopinto@medicina.ulisboa.pt
Conflict of interest: All authors affiliated with the company HeartGenetics, Genetics and Biotechnology
SA, declare that the company developed a genetic test, the MyVitDGenes®, that was used to evaluate all
the polymorphisms under analysis in this work. All other authors have declared that no conflict of interest
exists.
Keywords: Vitamin D deficiency, Vitamin D polymorphisms, Risk biomarkers, Population genetics,
Covid-19, Covid-19 severity
NOTE: This preprint reports new research..
Loading..
Please send us corrections, updates, or comments. Vaccines and
treatments are complementary. All practical, effective, and safe means should
be used based on risk/benefit analysis. No treatment, vaccine, or intervention
is 100% available and effective for all current and future variants. We do not
provide medical advice. Before taking any medication, consult a qualified
physician who can provide personalized advice and details of risks and
benefits based on your medical history and situation. FLCCC and WCH
provide treatment protocols.